Paul Ferguson, MBChB MRCP PhD^1*, Robert K Hills, DPhil², Angela Grech^3*, Sophie Betteridge^2*, Lars Kjeldsen, MD, PhD⁴, Michael Dennis, FRCPath^5*, Paresh Vyas, MD, PhD⁶, Alan K. Burnett, MD, FRCP⁷, Anthony H. Goldstone, FRCP, FRCPath⁸, Donald Milligan, MD⁹, Richard E. Clark, MD^10*, Nigel H. Russell, MD¹¹, Charles Craddock, MD PhD¹ and On behalf of the NCRI AML Working Group^12*

¹Centre for Clinical Haematology, Queen Elizabeth Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom
²Department of Haematology, Cardiff University School of Medicine, Cardiff, United Kingdom
³School of Medicine, Department of Haematology and Institute of Translation Innovation Methodology & Engagement, Cardiff University, Cardiff, United Kingdom
⁴Department of Hematology, Rigshospitalet, Copenhagen, Denmark
⁵The Christie NHS Foundation Trust, Manchester, United Kingdom
⁶MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine and Department of Haematology, University of Oxford and Oxford University Hospitals NHS Trust, UK, Oxford, United Kingdom
⁷Blackwaterfoot, Isle of Arran, United Kingdom
⁸Univ. College London Hosp., London, United Kingdom
⁹Department of Haematology & Stem Cell Transplantation, Birmingham Heartlands Hospital, Birmingham, United Kingdom
¹⁰Royal Liverpool University Hospital, Liverpool, United Kingdom
¹¹Centre for Clinical Haematology, Nottingham University Hospital, Nottingham, United Kingdom
¹²NCRI AML Working Group, London, United Kingdom

Lisa Eidenschink Brodersen, PhD^1*, Todd A. Alonzo, PhD^2,3, Andrew J. Menssen^1*, Robert B. Gerbing, MA^3*, Laura Pardo^4*, Andrew P. Voigt^1*, Samir B. Kahwash^5*, Betsy A. Hirsch, PhD^3,6*, Susana C. Raimondi, PhD^3,7, Alan S. Gamis, MD, MPH^3,8, Soheil Meshinchi, MD, PhD^3,9 and Michael R. Loken, PhD^1*

¹Hematologics Inc., Seattle, WA
²Keck School of Medicine, University of Southern California, Los Angeles, CA
³Children's Oncology Group, Monrovia, CA
⁴Hematologics, Inc, Seattle, WA
⁵Nationwide Children's Hospital, Columbus, OH
⁶University of Minnesota Medical Center, Minneapolis, MN
⁷Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN
⁸Division of Hematology/Oncology/Bone Marrow Transplantation, Children's Mercy Hospitals and Clinics, Kansas City, MO
⁹Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

Michael R. Loken, PhD^1*, Andrew P. Voigt^1*, Robert B. Gerbing, MA^2*, Lisa Eidenschink Brodersen, PhD^1*, Andrew J. Menssen^1*, Laura Pardo^3*, Alan S. Gamis, MD, MPH^2,4, Todd A. Alonzo, PhD^2,5 and Soheil Meshinchi, MD, PhD^2,6

¹Hematologics Inc., Seattle, WA
²Children's Oncology Group, Monrovia, CA
³Hematologics, Inc, Seattle, WA
⁴Division of Hematology/Oncology/Bone Marrow Transplantation, Children's Mercy Hospitals and Clinics, Kansas City, MO
⁵Keck School of Medicine, University of Southern California, Los Angeles, CA
⁶Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

Lindsay M Morton, PhD¹, Graca M. Dores, MD, MPH^1,2, Meredith S Shiels, PhD^1*, Martha S Linet, MD, MPH^3*, Jop C Teepen^4*, Clara J.K. Lam, PhD^5*, Margaret A. Tucker, MD^1* and Rochelle E Curtis, MA^3*

¹Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, MD
²Medical Service, Department of Veterans Affairs Medical Center, Oklahoma City, OK
³Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD
⁴Department of Epidemiology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
⁵Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, NIH, DHHS, Bethesda, MD

Anna Maria Testi, MD^1*, Andrea Pession, MD², David Grimwade, PhD, FRCPath³, Daniela Diverio, PhD^4*, Christine Ragu, PhD^5*, Sarah Elitzur, MD^6*, Alcira Fynn, MD^7*, Henrik Hasle, MD, PhD⁸, Jutte Van der Werff ten Bosch, MD, Phd^9*, Owen Smith, MD¹⁰, Brenda Gibson, MD^11*, Franco Locatelli, MD, PhD¹² and Gertjan J.L. Kaspers, MD, PhD¹³

¹Department of Cellular Biotechnologies and Hematology, Sapienza University of Rome, Rome, Italy
²Pediatric Unit, University of Bologna, Bologna, Italy
³Dept of Medical & Molecular Genetics, King's College London School of Medicine, London, United Kingdom
⁴Department of Cellular Biotechnologies and Hematology, University, Rome, Italy
⁵Department of Pediatric Hematology and Oncology, Trousseau Hospital, PARIS, France
⁶Pediatric Hematology Oncology, Schneider Children's Medical Center, Petah-Tikva, Israel
⁷Children's Hospital La Plata, La Plata, Argentina
⁸Department of Pediatrics, Aarhus University Hospital Skejby, Aarhus, Denmark
⁹Department of Pediatric, Universitair Zeikenhuis Brussel, Brussels, Belgium
¹⁰Oncology/ Haematology, Our Lady's Children's Hospital, Dublin, Ireland
¹¹Department of Pediatric Hematology, Royal Hospital for Children, Glasgow, United Kingdom
¹²University of Pavia, IRCCS Ospedale Pediatrico Bambino Gesł, Rome, Italy
¹³Dutch Childhood Oncology Group, The Hague, Netherlands

Tapan Kadia, MD¹, Jorge E. Cortes, MD², Farhad Ravandi, MD², Guillermo Garcia-Manero, MD², Michael Andreeff, MD, PhD², Koichi Takahashi, MD², Gautam Borthakur, MD², Elias J. Jabbour, MD², Kapil N. Bhalla, MD², Marina Konopleva, MD, PhD³, Naval Daver, MD², Courtney DiNardo, MD⁴, Prithviraj Bose, MD^2*, Keyur P. Patel, MD, PhD^5*, Sherry Pierce, BSN, BA^2* and Hagop M. Kantarjian, MD²

¹Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX
²Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
³Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
⁴University of Texas MD Anderson Cancer Center, Houston, TX
⁵Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX